Fundz

Igor Matushansky, MD, PhD, Joins Immuneering as Chief Medical Officer

PUBLIC · IMRXMar 20, 2025

Position

Chief Medical Officer

Company

Immuneering

Igor Matushansky
imatushansky@immuneering.com
CambridgeBiotechnologyHealthcareHealth CareMedicalTherapeutics

Description

Igor Matushansky, MD, PhD, has joined Immuneering as Chief Medical Officer. In his role, he will direct the company’s clinical activities, providing medical and operational leadership for the development programs.

Quick answer

Igor Matushansky, MD, PhD, Joins Immuneering as Chief Medical Officer (March 20, 2025). Immuneering is based in Cambridge, Massachusetts, United States.

Who is the new Chief Medical Officer at Immuneering?
Immuneering named Igor Matushansky Chief Medical Officer, announced March 20, 2025.
What did Immuneering announce on March 20, 2025?
Igor Matushansky, MD, PhD, has joined Immuneering as Chief Medical Officer. In his role, he will direct the company’s clinical activities, providing medical and operational leadership for the development programs.
What does Immuneering do?
Immuneering is a clinical-stage oncology company focused on keeping cancer patients alive.
Where is Immuneering based?
Immuneering is based in Cambridge, Massachusetts, United States.
Which similar companies made leadership changes around the same time?
Bristol Myers Squibb (March 20, 2025), Nanoscope Therapeutics (March 20, 2025), Acrivon Therapeutics (March 14, 2025) and Verrica (March 26, 2025) also announced leadership changes within 45 days of Immuneering.

Source: Fundz verified event record.

Other recent leadership changes in Healthcare and Medical

Executive moves at companies in the same sectors within 45 days, from Fundz verified event records.

Who to call at Immuneering, and when

A new leader at Immuneering brings new priorities and often new vendors. The first weeks are when they listen.

  • An alert the day Immuneering raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at Immuneering, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at Immuneering. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

Immuneering

Location

245 MAIN STREET, SECOND FLOOR

Cambridge, Massachusetts, United States

About

Immuneering is a clinical-stage oncology company focused on keeping cancer patients alive. The Company is developing an entirely new category of cancer medicines, Deep Cyclic Inhibitors. Immuneering’s lead product candidate, atebimetinib (IMM-1-104), is an oral, once-daily Deep Cyclic Inhibitor of MEK designed to improve durability and tolerability, and expand indications to include MAPK pathway-driven tumors such as most pancreatic cancers. Atebimetinib is currently in a Phase 2a trial in patients with advanced solid tumors including pancreatic cancer. The Company’s development pipeline also includes early-stage programs.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment Immuneering changes its leadership, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Related People

Igor
Likely contact at this company
••••••••@••••••••

See Igor's verified email →

Create an account to reveal verified emails
Predictive Intelligence
Strategic

ML-powered predictions for Immuneering's next move

Learn about Strategic plan

Immuneering changed its leadership. Fundz had it the day it was filed, with the decision-maker at the company attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.